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cAse RePoRt
A 25-year-old female was referred to the Haematology 
Unit at Tygerberg Hospital for further management of a 
rapidly expanding and large submandibular mass which 
on fine needle aspiration was suggestive of lymphoma 
(Figure 1). Five months earlier she had been diagnosed 
with pulmonary tuberculosis and was confirmed to be 
HIV positive with a CD4 count of 17. She was placed on 
anti-retroviral (ARV) and antituberculous therapy (the ARV 
therapy included efavirenz, emtricitabine and tenofivir). 
Her CD4 count, at the time of the current consultation, 
was 204 and the viral load was suppressed. Lumbar 
puncture was normal. Significant clinical findings were 
a large right submandibular mass and right cervical and 
axillary lymphadenopathy. The submandibular mass was 
removed and submitted for histological examination.
Macroscopic examination revealed a 62 gram, homo-
genous firm whitish-yellowish mass with areas of myxoid 
consistency. The size of the mass was 100 x 80 x 50 mm 
and, on cross section, neither necrosis nor haemorrhage 
was seen (Figure 2). Microscopic examination showed 
that the lesion was lymphoid in nature with relatively 
monomorphic cells with blue cytoplasm and nuclei 
that contained 3-5 nucleoli. High mitotic and apoptotic 
activity were seen as well as the presence of prominent 
scattered tingible body macrophages (ie. macrophages 
containing phagocytized, apoptotic cells in various states 
of degradation: “tingible” meaning stainable) (Figures 3 
and 4). A panel of immunohistochemical markers was 
done to type the lymphoma (Figure 5 and 6). The cells 
were positive for the following markers: CD45 (leukocyte 
common antigen, confirming the lymphoid nature of the 
neoplasm); the B-cell antigen, CD20 (confirming that the 
lymphoma is of B-cell origin); and germinal centre B-cell 
e Mosalleum: 1. BDS, MCHD, FCPath(SA). Division of Oral 
Pathology, Faculty of Dentistry, University of the Western Cape; 
National Health Laboratory Services, Tygerberg Hospital.
n Mohamed: 2. MBChB, MMed(Anat Path). Division of Anatomical 
Pathology, Stellenbosch University; National Health Laboratory 
Services, Tygerberg Hospital.
F Bassa: 3. MBChB, FCPath(Haem), MMed. Division of Clinical 
Haematology, Department of Medicine, Faculty of Health Sciences, 
Stellenbosch University.
wP Dreyer: 4. BDS, HDipDent, PhD, FCD(SA)OMP. Division of Oral 
Medicine and Periodontics, Faculty of Dentistry, University of the 
Western Cape; Professor Emeritus, Stellenbosch University.
corresponding author
wP Dreyer: 
 PO Box 1285, Sedgefield, 6573; E-mail wpd@sun.ac.za
saDJ May 2015, vol 70 no 4 p168 - p170
e Mosalleum1, n Mohamed2, Fc Bassa3, wP Dreyer4
AcRonYMs
ARV:   Antiretroviral 
FIsh:   Fluorescent in situ hybridization
hIV:   Human immunodeficiency virus 
cns:   Central nervous system
ct:   Computerized tomography 
ebV:   Epstein Barr Virus  
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Burkitt lymphoma of the oral cavity
Figure 1: The patient presented with a swelling in the right submandibular 
region. She also had trismus, which made intraoral examination very difficult 
but despite this, an intraoral exophytic soft tissue mass can be seen.
Figure 2: The tissue mass removed from the submandibular region showed a 
homogenous gelatinous consistency in cross section.
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antigens, CD10 and Bcl6 (confirming that the B-cell 
lymphoma derives from the lymphocytes in the germinal 
centre of the lymphoid follicle). The cells showed a 100% 
proliferative activity as illustrated by the Ki67, which is an 
immunohistochemical antibody that targets the tumour 
cells that are dividing or in a mitotic stage. 
The morphology of this case is typical of Burkitt lympho-
ma and, in order to confirm this provisional diagnosis, mo-
lecular confirmation of translocation (8;14) involving c-myc 
gene was requested. The molecular investigations using 
fluorescent in situ hybridization (FISH) showed the pres-
ence of that translocation (8;14), thus confirming a diag-
nosis of Burkitt lymphoma. Staging CT scan revealed Ann 
Arbor stage IV disease with extensive lymphadenopathy 
involving the right submandibular, mediastinal, para-
aortic, porta-hepatic and iliac nodes as well as splenic 
and hepatic involvement. There was no evidence of bony 
involvement. The patient received intensive combination 
chemotherapy together with continuation of ARV therapy. 
At the time of publication of this report, she had received 
four cycles of chemotherapy and showed an excellent in-
terim response.
dIscussIon 
Lymphomas are neoplasms that affect the lymphoid 
system. They are divided into two major categories; 
Hodgkin and non-Hodgkin lymphoma. The non-Hodgkin 
lymphomas are further sub-classified into B-cell and T-cell 
lymphomas with B-cell lymphomas showing a high level of 
morbidity in HIV positive patients. Burkitt lymphoma is a 
very aggressive high grade non-Hodgkin B-cell lymphoma 
that is derived from germinal centre lymphoid B cells. This 
neoplasm is the third most common malignancy in African 
children, preceded only by Wilms’ tumour (a rapidly 
developing malignant mixed tumour of the kidneys) and 
brain tumours. Burkitt lymphoma is named after Dennis 
Parsons Burkitt, a surgeon who first described the tumour 
in 1958 while working in equatorial Africa.1-3 
Burkitt lymphoma is classified into three variants:4-10
Endemic variant (also referred to as the African variant), •	
most commonly occurring in the jaws of children living 
in malaria endemic regions of the world (eg. equatorial 
Africa, Brazil and Papua New Guinea). The endemic 
form of Burkitt lymphoma accounts for 30-40% of 
malignancies in children living in equatorial Africa.4 
Interestingly, the distribution of the neoplasm in these 
areas corresponds to the distribution of endemic 
malaria, hence the term endemic Burkitt lymphoma. 
It is thought that chronic malaria reduces resistance 
to infection with the Epstein-Barr virus (EBV), a known 
oncogenic virus associated with endemic Burkitt 
lymphoma.4 The common age of presentation is 4 to 
7 years and the most common clinical presentation 
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Figure 3: The tumour revealed the starry sky appearance, typical of Burkitt 
lymphoma, at low magnification (H and E stain, original magnification x 100 ).
Figure 6: Immunohistochemistry of the proliferation marker Ki67 is very high, 
with the brown staining indicating cell nuclei in mitosis (original magnification 
x 400).
Figure 4: A higher power view of the H & E stained section highlights the 
morphology of the cells: the lymphocytes have a medium size and the 
scattered macrophages ( indicated by the arrows) contain tissue debris, 
and are commonly referred to as tingible body macrophages (original 
magnification X400).
Figure 5: The CD20 immunohistochemistry stain highlights the cell membrane 
of B-lymphocytes thus confirming that the neoplastic cells are of B-cell origin 
(original magnification X400).
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is as a jaw mass (58%), or abdominal mass including 
involvement of the ileum, kidneys and ovaries. The 
bone marrow and the central nervous system may 
also be involved.1,3,4,8 
Sporadic variant (also referred to as the non-African •	
variant), a variant not restricted to areas of endemic 
malaria and, although the tumour cells have a similar 
appearance to the endemic form, this tumour is rarely 
associated with EBV infection and is less commonly 
found in the jaws. It mainly involves the abdomen 
(88%), with rare involvement of the head and neck. 
There is no specific geographic association with this 
variant of Burkitt lymphoma, however, it is usually seen 
in European populations.1,3,4,6
Immunodeficiency associated subtype of Burkitt •	
lymphoma is frequently seen in Aids patients with a 
CD4 count below 200 cells/µL and can also be found 
in patients on immunosuppressive drugs following 
organ transplantation. It is considered to be one of 
the conditions signalling an underlying HIV infection.4-6 
Similar to the sporadic form, the immunodeficiency 
associated Burkitt lymphoma can be found in extra-
nodal sites such as this case presented above. The 
abdomen is also commonly involved and abdominal 
pain, vomiting, bowl obstruction and gastrointestinal 
bleeding constitutes the usual clinical presentation. In 
13-17% of patients the brain is involved.6
All forms of Burkitt lymphoma share the same morphol-
ogy and it is almost impossible to differentiate these three 
variants on microscopic features alone. The chromosomal 
rearrangement associated with c-myc oncogene expres-
sion is the hallmark of the molecular alterations in Burkitt 
lymphoma and this leads to the disturbance in germinal 
centre B-cell proliferation and differentiation. As could be 
expected, most of the cases seen in South Africa fall in the 
sporadic or HIV-associated variants.1
histopathology, genetic features and pathogenesis
The morphology and the immunohistochemistry of Burkitt 
lymphoma support an origin from the follicular centre 
B-lymphocytes. The tumour forms sheets of small to 
intermediate monomorphic lymphocytes with basophilic 
cytoplasm and central nuclei containing 3-5 nucleoli. High 
proliferative activity is reflected by the tumour cells and the 
scattered associated tingible body macrophages give rise 
to the characteristic picture of a starry sky appearance.4,7 
The immunodeficiency phenotype of Burkitt lymphoma 
is consistent with a B-cell lineage. The cells are reactive 
for CD20, CD19, CD22, and CD79a, which are antibodies 
that detect surface antigens of B lymphocytes. They 
also express germinal centre antibodies, such as can be 
demonstrated by immuno-staining for Bcl6 and CD10.5
The ability of EBV to transform the B-lymphocytes in 
Burkitt lymphoma is said to be amplified by malarial 
parasitaemia.4 This is why the endemic form of this 
lymphoma is common in the so-called lymphoma belt; 
an area between 10º south and 10º north of the equator, 
roughly corresponding to the area of endemic malaria.1 
However, additional mutations are required for the 
development of this lymphoma beside the involvement 
of EBV. These mutations generally involve chromosome 
8 and 14 and, at times, chromosome 2 and 8.4, 6, 7
Treatment and prognosis
Chemotherapy is the primary treatment modality for 
patients with Burkitt lymphoma. The neoplastic cells 
are very sensitive to cytotoxic therapy and intensive 
multi-agent chemotherapy regimens are recommended 
in Burkitt lymphoma patients who are HIV negative. 
In HIV positive patients, these protocols are modified 
in order to reduce toxicity particularly in patients who 
are ARV therapy naïve.4,7,11 Involvement of the central 
nervous system (CNS), bone marrow and HIV infection 
indicate a less favourable outcome and therefore CNS 
chemoprophylaxis is advocated.4,7 A recent study in a 
Korean population showed that the two-year survival 
rates are lower in patients with bone marrow and CNS 
involvement, however, involvement of other extra-nodal 
sites had no effect on the prognosis.8 Therefore, a good 
understanding of the pathogenesis associated with the 
different subtypes is essential for the development of new 
chemotherapeutic therapeutic strategies.7 
conclusIon
Burkitt lymphoma is a very aggressive fast growing non-
Hodgkin lymphoma. The importance of early diagnosis and 
treatment cannot be overemphasized as treatment success 
is dependent on the extent of disease. Burkitt lymphoma is 
one of the human cancers that highlight the role of viruses 
in the carcinogenic process and, as a consequence, 
it is one of the lymphomas that develop in persons who 
are immunodeficient, either as a result of HIV infection or 
subsequent to organ transplantation. Knowledge about the 
clinical presentation, usual extra-nodal involvement and the 
subtypes of this lymphoma is essential for making an early 
diagnosis and therefore can make a significant difference in 
the prognosis of the afflicted patient.
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